De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

United Laboratories International Holdings Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	no data
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	13.9yrs

Recente managementupdates

Did The United Laboratories International Holdings Limited (HKG:3933) Insiders Sell Shares?

Jan 19

Recent updates

Here's Why We Think United Laboratories International Holdings (HKG:3933) Is Well Worth Watching

Aug 30

Improved Earnings Required Before The United Laboratories International Holdings Limited (HKG:3933) Stock's 26% Jump Looks Justified

Feb 29

The United Laboratories International Holdings Limited's (HKG:3933) Low P/E No Reason For Excitement

Jan 04

United Laboratories International Holdings (HKG:3933) Could Easily Take On More Debt

Dec 14

With EPS Growth And More, United Laboratories International Holdings (HKG:3933) Makes An Interesting Case

Nov 26

Is United Laboratories International Holdings (HKG:3933) A Risky Investment?

Aug 31

Does United Laboratories International Holdings (HKG:3933) Deserve A Spot On Your Watchlist?

Aug 10

United Laboratories International Holdings (HKG:3933) Has A Rock Solid Balance Sheet

Dec 23

Are Investors Undervaluing The United Laboratories International Holdings Limited (HKG:3933) By 47%?

Oct 19

Is United Laboratories International Holdings (HKG:3933) Using Too Much Debt?

Aug 30

Is The United Laboratories International Holdings Limited (HKG:3933) A Smart Pick For Income Investors?

Mar 08

The United Laboratories International Holdings (HKG:3933) Share Price Is Up 108% And Shareholders Are Boasting About It

Feb 18

The United Laboratories International Holdings Limited's (HKG:3933) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 03

Did The United Laboratories International Holdings Limited (HKG:3933) Insiders Sell Shares?

Jan 19

We Wouldn't Rely On United Laboratories International Holdings's (HKG:3933) Statutory Earnings As A Guide

Jan 04

These 4 Measures Indicate That United Laboratories International Holdings (HKG:3933) Is Using Debt Safely

Dec 20

What Type Of Shareholders Own The Most Number of The United Laboratories International Holdings Limited (HKG:3933) Shares?

Dec 07

The United Laboratories International Holdings Limited (HKG:3933) Is Yielding 1.3% - But Is It A Buy?

Nov 23

CEO

United Laboratories International Holdings heeft geen CEO, of we hebben geen gegevens over hen.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Hoi Shan Tsoi	Executive Chairman	15.5yrs	CN¥4.20m	0.90% HK$ 174.5m
Wing Hon Leung	Vice Chairman	17.9yrs	CN¥4.17m	0.0012% HK$ 235.3k
Su Yan Zhu	VP & Executive Director	13.9yrs	CN¥2.52m	0.000010% HK$ 1.9k
Xian Hong Zou	VP & Executive Director	13.9yrs	CN¥2.52m	0.011% HK$ 2.1m
Siu Chit Choy	Global Director of Intermediate & Bulk Medicine and Executive Director	11.3yrs	CN¥2.80m	0.0065% HK$ 1.3m
Yu Ping Fang	VP & Executive Director	13.9yrs	CN¥2.55m	geen gegevens
Ming Song	Independent Non-Executive Director	17.4yrs	CN¥234.00k	geen gegevens
Peng Oon Chong	Independent Non-Executive Director	15.6yrs	CN¥234.00k	geen gegevens
Qiushi Fu	Independent Non-Executive Director	1.3yrs	CN¥118.00k	geen gegevens

13.9yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 3933 zijn ervaren en ervaren (gemiddelde ambtstermijn van 13.9 jaar).

United Laboratories International Holdings Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

the United Laboratories International Holdings Limited Announces Appointment of Dr. Fu Qiushi as Independent Non-Executive Director and A Member of the Audit Committee, the Remuneration Committee and the Nomination Committee

Less than half of directors are independent

Less than half of directors are independent

Did The United Laboratories International Holdings Limited (HKG:3933) Insiders Sell Shares?

Recent updates

The United Laboratories International Holdings Limited Announces the Application for Marketing of Insulin Degludec Injection

First half 2024 earnings: EPS exceeds analyst expectations

Here's Why We Think United Laboratories International Holdings (HKG:3933) Is Well Worth Watching

The United Laboratories International Holdings Limited Declares Interim Dividend for the Six Months Ended 30 June 2024

The United Laboratories International Holdings Limited to Report First Half, 2024 Results on Aug 29, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Investor sentiment improves as stock rises 16%

The United Laboratories International Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Improved Earnings Required Before The United Laboratories International Holdings Limited (HKG:3933) Stock's 26% Jump Looks Justified

The United Laboratories International Holdings Limited's (HKG:3933) Low P/E No Reason For Excitement

United Laboratories International Holdings (HKG:3933) Could Easily Take On More Debt

With EPS Growth And More, United Laboratories International Holdings (HKG:3933) Makes An Interesting Case

New minor risk - Share price stability

Price target increased by 18% to HK$10.66

Price target increased by 8.4% to HK$9.06

The United Laboratories International Holdings Limited Announces FDA Approval of IND for UBT251 Injection

the United Laboratories International Holdings Limited Announces Interim Dividend for Six Months Ended 30 June 2023, Payable on 11 October 2023

Investor sentiment deteriorates as stock falls 17%

Price target increased by 12% to HK$8.36

The United Laboratories International Holdings Limited Announces Application for the Clinical Trial of Class 1 Innovative New Drug UBT251 Injection

First half 2023 earnings released: EPS: CN¥0.71 (vs CN¥0.34 in 1H 2022)

the United Laboratories International Holdings Limited Announces Ordinary Interim (Semi-Annual) Dividend for Six Months Ended 30 June 2023

Is United Laboratories International Holdings (HKG:3933) A Risky Investment?

New major risk - Revenue and earnings growth

The United Laboratories International Holdings Limited to Report First Half, 2023 Results on Aug 29, 2023

Investor sentiment improves as stock rises 17%

Does United Laboratories International Holdings (HKG:3933) Deserve A Spot On Your Watchlist?

the United Laboratories International Holdings Limited Announces Appointment of Dr. Fu Qiushi as Independent Non-Executive Director and A Member of the Audit Committee, the Remuneration Committee and the Nomination Committee

The United Laboratories International Holdings Limited Approves Special Dividend for the Year Ended 31 December 2022

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 7.4% to HK$5.85

Investor sentiment improves as stock rises 19%

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to HK$5.42

United Laboratories International Holdings (HKG:3933) Has A Rock Solid Balance Sheet

Investor sentiment improved over the past week

Less than half of directors are independent

Are Investors Undervaluing The United Laboratories International Holdings Limited (HKG:3933) By 47%?

The United Laboratories International Holdings Limited Announces Approval of Marketing of Sodium Hyaluronate Eye Drops Applied by Zhuhai United Laboratories Co., Ltd

The United Laboratories International Holdings Limited (SEHK:3933) commences an Equity Buyback Plan for 181,757,450 shares, representing 10% of its issued share capital, under the authorization approved on June 21, 2022.

The United Laboratories International Holdings Limited Announces an Interim Dividend for the Year 2022, Payable on 6 October 2022

Price target decreased to HK$5.02

The United Laboratories International Holdings Limited Announces Interim Dividend for the Six Months Ended 30 June 2022

First half 2022 earnings released: EPS: CN¥0.35 (vs CN¥0.34 in 1H 2021)

The United Laboratories International Holdings Limited Approves Special Dividend for the Year Ended 31 December 2021, Payable on 20 July 2022

The United Laboratories International Holdings Limited Approves Final Dividend for the Year Ended 31 December 2021

Investor sentiment improved over the past week

Price target decreased to HK$5.54

Full year 2021 earnings: EPS misses analyst expectations

Price target decreased to HK$6.38

Less than half of directors are independent

Investor sentiment improved over the past week

Price target decreased to HK$7.34

The United Laboratories International Holdings Limited (SEHK:3933) commences an Equity Buyback Plan for 184,039,050 shares, representing 10% of its issued share capital, under the authorization approved on June 22, 2021.

Investor sentiment deteriorated over the past week

Is United Laboratories International Holdings (HKG:3933) Using Too Much Debt?

First half 2021 earnings released: EPS CN¥0.34 (vs CN¥0.12 in 1H 2020)

Investor sentiment deteriorated over the past week

The United Laboratories International Holdings Limited Announces Updated Information of the Group's Products

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.39 in FY 2019)

Consensus forecasts updated

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.39 in FY 2019)

The United Laboratories International Holdings Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

Is The United Laboratories International Holdings Limited (HKG:3933) A Smart Pick For Income Investors?

The United Laboratories International Holdings (HKG:3933) Share Price Is Up 108% And Shareholders Are Boasting About It

The United Laboratories International Holdings Limited's (HKG:3933) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Investor sentiment improved over the past week

Did The United Laboratories International Holdings Limited (HKG:3933) Insiders Sell Shares?

New 90-day low: HK$5.12

We Wouldn't Rely On United Laboratories International Holdings's (HKG:3933) Statutory Earnings As A Guide

New 90-day low: HK$5.40